AR097619A1 - Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris - Google Patents
Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgarisInfo
- Publication number
- AR097619A1 AR097619A1 ARP140103378A ARP140103378A AR097619A1 AR 097619 A1 AR097619 A1 AR 097619A1 AR P140103378 A ARP140103378 A AR P140103378A AR P140103378 A ARP140103378 A AR P140103378A AR 097619 A1 AR097619 A1 AR 097619A1
- Authority
- AR
- Argentina
- Prior art keywords
- acné
- acetil
- vulgaris
- treat
- coa carboxylase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Reivindicación 1: El uso de un inhibidor ACC, o una sal farmacéuticamente aceptable del mismo, por la elaboración de un medicamento para el tratamiento de acné. Reivindicación 2: El uso de una composición farmacéutica que comprende un inhibidor ACC o una sal farmacéuticamente aceptable del mismo, y al menos un portador farmacéuticamente aceptable del mismo en la elaboración de un medicamento para el tratamiento de acné. Reivindicación 5: El uso de 1-(2-aminoquinolin-7-carbonil)-1-isopropil-4,6-dihidroespiro[indazol-5,4-piperidin]-7(1H)-ona, o una sal farmacéuticamente aceptable del mismo, en la elaboración de un medicamento para el tratamiento de acné.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361877058P | 2013-09-12 | 2013-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR097619A1 true AR097619A1 (es) | 2016-04-06 |
Family
ID=51541122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140103378A AR097619A1 (es) | 2013-09-12 | 2014-09-10 | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20160220557A1 (es) |
| EP (1) | EP3043800A1 (es) |
| JP (1) | JP2016534091A (es) |
| KR (1) | KR20160042089A (es) |
| CN (1) | CN105530940A (es) |
| AR (1) | AR097619A1 (es) |
| AU (1) | AU2014319990A1 (es) |
| BR (1) | BR112016004118A2 (es) |
| CA (1) | CA2923884A1 (es) |
| HK (1) | HK1217448A1 (es) |
| IL (1) | IL243969A0 (es) |
| MX (1) | MX2016002479A (es) |
| RU (1) | RU2016106829A (es) |
| SG (1) | SG11201600711PA (es) |
| TW (1) | TW201521722A (es) |
| WO (1) | WO2015036892A1 (es) |
| ZA (1) | ZA201601084B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017147161A1 (en) * | 2016-02-23 | 2017-08-31 | Raju Mohan | Treatment of dermatological disorders or conditions |
| BR112019028027A2 (pt) | 2017-06-30 | 2020-07-07 | Quixgen, Inc. | compostos de espirolactona inovadores |
| WO2019072478A1 (en) | 2017-10-10 | 2019-04-18 | Galderma Research & Development | SPECIFIC ACETYL-COA CARBOXYLASE INHIBITORS FOR USE IN THE TREATMENT AND / OR PREVENTION OF ACNE |
| TW201930265A (zh) | 2017-12-11 | 2019-08-01 | 西班牙商阿爾米雷爾有限公司 | 作為acc抑制劑的吡咯衍生物 |
| GB201812561D0 (en) * | 2018-08-01 | 2018-09-12 | Univ Manchester | Biomarkers and uses thereof |
| WO2020245291A1 (en) | 2019-06-06 | 2020-12-10 | Almirall, S.A. | Pyrrole derivatives as acc inhibitors |
| WO2020245297A1 (en) | 2019-06-06 | 2020-12-10 | Almirall, S.A. | Pyrrole derivatives as acc inhibitors |
| CN111574530B (zh) * | 2020-04-21 | 2022-07-26 | 徐州医科大学 | 一种acc抑制剂及其医药用途 |
| EP4014964A1 (en) | 2020-12-21 | 2022-06-22 | Almirall S.A. | Topical formulation |
| WO2023090411A1 (ja) | 2021-11-19 | 2023-05-25 | 塩野義製薬株式会社 | 心疾患または骨格筋の疾患の治療用医薬 |
| US20240109915A1 (en) * | 2022-07-29 | 2024-04-04 | Pfizer Inc. | Novel acc inhibitors |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5855897A (en) * | 1996-09-13 | 1999-01-05 | E-L Management Corp. | Topical composition and method for enhancing lipid barrier synthesis |
| JPH11171848A (ja) | 1997-09-26 | 1999-06-29 | Fujirebio Inc | 芳香族アミド誘導体 |
| JPH11171847A (ja) | 1997-09-26 | 1999-06-29 | Fujirebio Inc | ブタン酸アミド誘導体 |
| US6120756A (en) * | 1998-08-19 | 2000-09-19 | Philip I. Markowitz | Topical anionic salicylate for disorders of the skin |
| KR20020060737A (ko) | 1999-11-12 | 2002-07-18 | 추후보정 | 암세포를 선택적으로 사멸시키기 위한 수단으로서의세포내 조효소 ａ 농도의 감소 방법 |
| EP1423381B1 (en) * | 2001-09-06 | 2007-01-03 | Schering Corporation | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| JP2005194191A (ja) | 2001-12-28 | 2005-07-21 | Ajinomoto Co Inc | 抗肥満薬、脂肪肝治療薬 |
| JP2005162612A (ja) | 2002-01-09 | 2005-06-23 | Ajinomoto Co Inc | アシルスルホンアミド誘導体 |
| KR20040095239A (ko) | 2002-02-27 | 2004-11-12 | 화이자 프로덕츠 인코포레이티드 | Ａｃｃ 억제제 |
| US6485941B1 (en) | 2002-04-23 | 2002-11-26 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Inhibition of the carboxyltransferase component of acetyl-CoA carboxylase, and the use of such inhibition in anti-cancer and anti-lipogenic therapies |
| US7211423B2 (en) | 2004-07-23 | 2007-05-01 | Bristol-Myers Squibb Co. | Acetyl CoA carboxylase 2 sequences and methods |
| WO2006017494A2 (en) | 2004-08-02 | 2006-02-16 | Elizabeth Mazzio | Inhibition of anaerobic glucose metabolism |
| US20060178400A1 (en) | 2004-11-05 | 2006-08-10 | Beutel Bruce A | Novel acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome |
| CA2603206A1 (en) | 2005-04-08 | 2006-10-19 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to acetyl-coa carboxylases |
| JPWO2007013691A1 (ja) | 2005-07-29 | 2009-02-12 | 武田薬品工業株式会社 | スピロ環化合物 |
| JP2007161630A (ja) * | 2005-12-13 | 2007-06-28 | Adeka Corp | 皮脂抑制剤 |
| CN101421255A (zh) | 2006-02-15 | 2009-04-29 | 艾博特公司 | 新的乙酰辅助a羧化酶（acc）抑制剂及其在糖尿病、肥胖症和代谢综合症中的应用 |
| US8735595B2 (en) | 2006-02-15 | 2014-05-27 | Abbvie Inc. | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome |
| EP1999119A2 (en) | 2006-02-15 | 2008-12-10 | Abbott Laboratories | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome |
| EP2009011A1 (en) | 2006-04-14 | 2008-12-31 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
| WO2008058034A1 (en) * | 2006-11-03 | 2008-05-15 | Qlt Inc. | Methods of treating dermatological disorders or conditions |
| KR20080052024A (ko) | 2006-12-07 | 2008-06-11 | (주)아모레퍼시픽 | 아세틸-조효소 ａ 카복실라제 저해활성을 갖는트리아졸로피리다진 유도체 |
| WO2008072850A1 (en) | 2006-12-11 | 2008-06-19 | Amorepacific Corporation | Triazine derivatives having inhibitory activity against acetyl-coa carboxylase |
| US7928243B2 (en) | 2006-12-21 | 2011-04-19 | Abbott Laboratories | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome |
| JP2008179621A (ja) | 2006-12-28 | 2008-08-07 | Taisho Pharmaceutical Co Ltd | 含窒素飽和複素環化合物 |
| PE20081559A1 (es) | 2007-01-12 | 2008-11-20 | Merck & Co Inc | DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA |
| WO2008090944A1 (ja) | 2007-01-25 | 2008-07-31 | Takeda Pharmaceutical Company Limited | スピロ環化合物 |
| US20100113418A1 (en) | 2007-02-20 | 2010-05-06 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US20090005375A1 (en) | 2007-03-30 | 2009-01-01 | Edcon Chang | Acetyl coenzyme a carboxylase inhibitors |
| JP2010527360A (ja) | 2007-05-14 | 2010-08-12 | ニューエラ・ファーマシューティカルズ・インコーポレーテッド | 神経細胞の代謝低下の処置のためのアセチル−ｃｏａカルボキシラーゼの阻害剤 |
| JP5616220B2 (ja) | 2007-06-01 | 2014-10-29 | ザ トラスティーズ オブ プリンストン ユニバーシティ | 宿主細胞代謝経路の調節によるウイルス感染治療 |
| WO2009055682A1 (en) | 2007-10-26 | 2009-04-30 | Janssen Pharmaceutica N.V. | Crystal structure of the carboxyl transferase domain of human acetyl-coa carboxylase 2 protein (acc2 ct) and uses thereof |
| JP2009196966A (ja) | 2008-02-25 | 2009-09-03 | Takeda Chem Ind Ltd | ピラゾリジンジオン誘導体 |
| US7981904B2 (en) | 2008-03-20 | 2011-07-19 | Takeda Pharmaceutical Company Limited | Acetyl CoA carboxylase inhibitors |
| WO2009144555A1 (en) | 2008-05-28 | 2009-12-03 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| EP2297163B1 (en) | 2008-05-28 | 2015-07-08 | Pfizer Inc. | Pyrazolospiroketone acetyl-CoA carboxylase inhibitors |
| US8524730B2 (en) | 2008-07-04 | 2013-09-03 | Msd K.K. | Spirochromanone carboxylic acids |
| JP2010043019A (ja) | 2008-08-12 | 2010-02-25 | Taisho Pharmaceutical Co Ltd | ピペリジニルピペラジン化合物 |
| EP2351743A4 (en) | 2008-10-27 | 2012-05-09 | Takeda Pharmaceutical | BICYCLIC COMPOUND |
| US20100113473A1 (en) | 2008-10-30 | 2010-05-06 | Player Mark R | Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor |
| WO2010127208A1 (en) | 2009-04-30 | 2010-11-04 | Forest Laboratories Holdings Limited | Inhibitors of acetyl-coa carboxylase |
| WO2010127212A1 (en) | 2009-04-30 | 2010-11-04 | Forest Laboratories Holdings Limited | Inhibitors of acetyl-coa carboxylase |
| BR112012000254A2 (pt) | 2009-07-08 | 2016-02-16 | Dermira Canada Inc | análogos de tofa úteis no tratamento de distúrbios ou condições dermatológicas. |
| EP2947082A1 (en) | 2009-11-10 | 2015-11-25 | Pfizer Inc | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS |
| CN101876925B (zh) | 2009-11-27 | 2012-05-02 | 成都市华为赛门铁克科技有限公司 | 内存镜像处理方法、装置和系统 |
| US8394858B2 (en) | 2009-12-03 | 2013-03-12 | Novartis Ag | Cyclohexane derivatives and uses thereof |
| DE102010008642A1 (de) | 2010-02-15 | 2011-08-18 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Zyklische Ketoenole zur Therapie |
| DE102010008644A1 (de) | 2010-02-15 | 2011-08-18 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Zyklische Ketoenole zur Therapie |
| DE102010008643A1 (de) | 2010-02-15 | 2011-08-18 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Zyklische Ketoenole zur Therapie |
| JP2011225455A (ja) | 2010-04-15 | 2011-11-10 | Kao Corp | Ｓｒｅｂｐ抑制剤 |
| UA108102C2 (uk) | 2010-04-27 | 2015-03-25 | Біциклічні похідні і їх застосування як інгібіторів асс | |
| US9006450B2 (en) | 2010-07-01 | 2015-04-14 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| US8697739B2 (en) | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
| US20120129833A1 (en) | 2010-08-20 | 2012-05-24 | Bayer Pharma Aktiengesellschaft | Cyclic ketoenols for therapy |
| US8835472B2 (en) | 2010-09-02 | 2014-09-16 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| US8877754B2 (en) | 2010-09-06 | 2014-11-04 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| EP2632925B1 (en) | 2010-10-29 | 2015-05-27 | Pfizer Inc | N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS |
| CA2819400A1 (en) | 2010-11-30 | 2012-06-07 | Takeda Pharmaceutical Company Limited | Bicyclic compound |
| WO2012090219A2 (en) | 2010-12-31 | 2012-07-05 | Jubilant Biosys Ltd. | Thiazole compounds useful as acetyl-coa carboxylase (acc) inhibitors |
| AP2013007057A0 (en) | 2011-02-06 | 2013-08-31 | Bayer Ip Gmbh | (5S,8S)-3-(4'chlor-3'-fluor-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one(compound A)for treatment |
| WO2012108478A1 (ja) | 2011-02-09 | 2012-08-16 | 武田薬品工業株式会社 | 単環化合物 |
| ES2561452T3 (es) * | 2011-04-22 | 2016-02-26 | Pfizer Inc | Derivados de pirazoloespirocetona para su uso como inhibidores de acetil-CoA carboxilasa |
| DE102011080406A1 (de) | 2011-08-04 | 2013-02-07 | Bayer Pharma AG | Substituierte 3-(Biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro8[4.5]dec-3-en-2-one |
| US8844103B2 (en) | 2011-09-01 | 2014-09-30 | Medtronic, Inc. | Methods for making feedthrough assemblies including a capacitive filter array |
| WO2013035827A1 (ja) | 2011-09-09 | 2013-03-14 | 塩野義製薬株式会社 | 新規オレフィン誘導体 |
| CN103998432A (zh) | 2011-10-24 | 2014-08-20 | 武田药品工业株式会社 | 双环化合物 |
| KR102033806B1 (ko) | 2011-11-11 | 2019-10-17 | 길리어드 아폴로, 엘엘씨 | Ａｃｃ 억제제 및 이의 용도 |
| EP2785690B1 (en) | 2011-12-02 | 2016-07-13 | Boehringer Ingelheim International GmbH | Piperidine derivatives, pharmaceutical compositions and uses thereof |
| US8765959B2 (en) | 2011-12-23 | 2014-07-01 | Boehringer Ingelheim International Gmbh | Piperidine derivatives |
| US8530461B2 (en) | 2011-12-29 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Azetidine derivatives |
| US8623860B2 (en) | 2011-12-30 | 2014-01-07 | Boehringer Ingelheim International Gmbh | Azetidine derivatives, pharmaceutical compositions and uses thereof |
-
2014
- 2014-08-29 MX MX2016002479A patent/MX2016002479A/es unknown
- 2014-08-29 AU AU2014319990A patent/AU2014319990A1/en not_active Abandoned
- 2014-08-29 BR BR112016004118A patent/BR112016004118A2/pt not_active IP Right Cessation
- 2014-08-29 EP EP14766222.5A patent/EP3043800A1/en not_active Withdrawn
- 2014-08-29 SG SG11201600711PA patent/SG11201600711PA/en unknown
- 2014-08-29 CA CA2923884A patent/CA2923884A1/en not_active Abandoned
- 2014-08-29 RU RU2016106829A patent/RU2016106829A/ru not_active Application Discontinuation
- 2014-08-29 CN CN201480049771.8A patent/CN105530940A/zh active Pending
- 2014-08-29 US US15/021,010 patent/US20160220557A1/en not_active Abandoned
- 2014-08-29 JP JP2016527435A patent/JP2016534091A/ja active Pending
- 2014-08-29 WO PCT/IB2014/064151 patent/WO2015036892A1/en active Application Filing
- 2014-08-29 KR KR1020167006341A patent/KR20160042089A/ko not_active Application Discontinuation
- 2014-09-09 TW TW103131010A patent/TW201521722A/zh unknown
- 2014-09-10 AR ARP140103378A patent/AR097619A1/es unknown
-
2016
- 2016-02-04 IL IL243969A patent/IL243969A0/en unknown
- 2016-02-17 ZA ZA2016/01084A patent/ZA201601084B/en unknown
- 2016-05-16 HK HK16105585.2A patent/HK1217448A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2923884A1 (en) | 2015-03-19 |
| EP3043800A1 (en) | 2016-07-20 |
| WO2015036892A1 (en) | 2015-03-19 |
| TW201521722A (zh) | 2015-06-16 |
| KR20160042089A (ko) | 2016-04-18 |
| BR112016004118A2 (pt) | 2017-10-17 |
| RU2016106829A (ru) | 2017-10-17 |
| SG11201600711PA (en) | 2016-03-30 |
| IL243969A0 (en) | 2016-04-21 |
| MX2016002479A (es) | 2016-05-31 |
| ZA201601084B (en) | 2017-05-31 |
| US20160220557A1 (en) | 2016-08-04 |
| JP2016534091A (ja) | 2016-11-04 |
| AU2014319990A1 (en) | 2016-02-25 |
| HK1217448A1 (zh) | 2017-01-13 |
| CN105530940A (zh) | 2016-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
| CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
| SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| BR112015020466A8 (pt) | inibidores de cdc7, seus usos, e composição farmacêutica | |
| CL2018000706A1 (es) | Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer. | |
| CL2016001604A1 (es) | “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct | |
| BR112015026006A2 (pt) | métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor | |
| UY35907A (es) | Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmaceuticas que las contienen, así como su uso para la preparación de medicamentos | |
| BR112016024545A2 (pt) | derivados de pirazolo pirimidina e seu uso como inibidores de malt1 | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| GT201500053A (es) | Composicion farmaceutica recubierta que contiene regorafenib | |
| WO2015054619A8 (en) | Use of a pcsk9 inhibitor to treat hyperlipidemia | |
| PH12016502355A1 (en) | Pharmaceutical composition | |
| AR087107A1 (es) | Compuesto inhibidor de la señalizacion de la trayectoria notch | |
| MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
| NI201400111A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| AR102973A1 (es) | Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende | |
| AR103680A1 (es) | Inhibidores selectivos de bace1 | |
| GT201400059A (es) | Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos | |
| CL2017000050A1 (es) | Terapia de combinación para el cáncer | |
| CL2015000039A1 (es) | Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis. | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| NI201800071A (es) | Compuestos de isoindol | |
| CL2015002847A1 (es) | Sistemas y métodos para tratar una respuesta farmacodinámica adversa inducida por opioides (divisional de la solicitud n° 0110-2015). | |
| BR112016005317A2 (pt) | derivados de quinazolina e seu uso como inibidores de dna metiltransferase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |